Oncology Research and Development, Pfizer Inc., San Diego, California, USA.
Oncology Medicinal Chemistry, Pfizer Inc., San Diego, California, USA.
Nat Chem Biol. 2017 Jul;13(7):785-792. doi: 10.1038/nchembio.2384. Epub 2017 May 29.
S-Adenosyl-L-methionine (SAM) is an enzyme cofactor used in methyl transfer reactions and polyamine biosynthesis. The biosynthesis of SAM from ATP and L-methionine is performed by the methionine adenosyltransferase enzyme family (Mat; EC 2.5.1.6). Human methionine adenosyltransferase 2A (Mat2A), the extrahepatic isoform, is often deregulated in cancer. We identified a Mat2A inhibitor, PF-9366, that binds an allosteric site on Mat2A that overlaps with the binding site for the Mat2A regulator, Mat2B. Studies exploiting PF-9366 suggested a general mode of Mat2A allosteric regulation. Allosteric binding of PF-9366 or Mat2B altered the Mat2A active site, resulting in increased substrate affinity and decreased enzyme turnover. These data support a model whereby Mat2B functions as an inhibitor of Mat2A activity when methionine or SAM levels are high, yet functions as an activator of Mat2A when methionine or SAM levels are low. The ramification of Mat2A activity modulation in cancer cells is also described.
S-腺苷-L-蛋氨酸(SAM)是一种酶辅因子,用于甲基转移反应和多胺生物合成。SAM 由三磷酸腺苷(ATP)和 L-蛋氨酸通过蛋氨酸腺苷转移酶酶家族(Mat;EC 2.5.1.6)合成。人类蛋氨酸腺苷转移酶 2A(Mat2A)是一种肝外同工酶,在癌症中经常失调。我们鉴定了一种 Mat2A 抑制剂 PF-9366,它结合 Mat2A 的别构位点,该位点与 Mat2A 调节剂 Mat2B 的结合位点重叠。利用 PF-9366 进行的研究提出了 Mat2A 别构调节的一般模式。PF-9366 或 Mat2B 的别构结合改变了 Mat2A 的活性位点,导致底物亲和力增加和酶周转率降低。这些数据支持这样一种模型,即当蛋氨酸或 SAM 水平较高时,Mat2B 作为 Mat2A 活性的抑制剂起作用,但当蛋氨酸或 SAM 水平较低时,Mat2B 作为 Mat2A 的激活剂起作用。还描述了癌细胞中 Mat2A 活性调节的后果。